Fertility in patients with multiple sclerosis: current knowledge and future perspectives.
The issue of fertility in patients with multiple sclerosis (MS) has not been exhaustively studied. Epidemiological data have suggested that spontaneous fecundity might be reduced; several endocrine and sexual disturbances potentially interfering with reproduction have been evidenced in MS patients of both sexes. Moreover, some medical treatments used in MS (e. g., mitoxantrone, cyclophosphamide) may exert detrimental effects on spermatozoa as well as on oocytes, leading to early impairment of fertility. This review illustrates the factors potentially interfering with fertility in MS and discusses the therapeutic tools that may be used to promote fertility in these patients. The safety of hormonal therapies in MS is also examined. The current applications of assisted reproductive technology (ART) are discussed, including in vitro fertilisation (IVF) techniques. Currently available methods to preserve fertility in patients that undergo cytotoxic treatments by means of sperm/oocyte cryostorage or by ovarian fragment cryopreservation and autografting are considered.
Cavalla
P
P
Department of Neurosciences, University of Turin, Turin, Italy.
Rovei
V
V
Masera
S
S
Vercellino
M
M
Massobrio
M
M
Mutani
R
R
Revelli
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005298:Fertility / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy; D027724:Reproductive Techniques, Assisted
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D008942:Mitoxantrone